why choose us

300×250 Ad Slot

Research Article: AHSA Regulates Hepatocellular Carcinoma Progression via the TGF-?/Akt-Cyclin D/CDK Pathway

Date Published: 2023-11-08

Abstract:
Hepatocellular carcinoma (HCC) is the sixth most common and malignant tumor worldwide and the third leading cause of cancer-related mortality in China., The risk factors associated with HCC include viral hepatitis, particularly hepatitis B virus infection as the most important factor, alcoholic liver disease, nonalcoholic fatty liver disease, metabolic syndrome, and so forth. The poor prognosis of HCC is mainly because most patients with HCC are in the intermediate and advanced stages when they are diagnosed and have a survival time of less than – months. Patients with early-stage liver cancer can undergo surgery or radiofrequency ablation. The age-standardized -year relative survival rate for HCC is only .%., Sorafenib and lenvatinib, as two clinically approved targeted-therapy drugs, could extend the overall survival only by – months., Immunotherapy has many issues, such as uncertain efficacy, low objective remission rate, numerous side effects, and drug resistance even if patients benefit from it., Therefore, novel HCC targets and pathogenesis are urgently needed.

Introduction:
Hepatocellular carcinoma (HCC) is the sixth most common and malignant tumor worldwide and the third leading cause of cancer-related mortality in China. , The risk factors associated with HCC include viral hepatitis, particularly hepatitis B virus infection as the most important factor, alcoholic liver disease, nonalcoholic fatty liver disease, metabolic syndrome, and so forth. The poor prognosis of HCC is mainly because most patients with HCC are in the intermediate and advanced stages when they are diagnosed and…

Read more

300×250 Ad Slot